Avalia - Treatment Therapy for cHBV
Avalia’s lead programme, is focused on a necessary cure for individuals infected with chronic HBV. It aims to provide superior activation of the innate and adaptive immune system, to overcome immune tolerance and generate a highly targeted immune response against HBV in the liver to eliminate infected cells – the desired immune response to achieve a functional cure.
Because Avalia’s immune therapies are liver-targeting, they also generate memory T cells in the liver. These cells have the long-term ability to seek and eliminate HBV-infected cells. This family of T cells, referred to as liver tissue-resident memory T cells have been reported in recent scientific journals as the potential key to the clearance of HBV.
Despite the availability of preventative vaccines, 2 billion people worldwide have been infected, with the liver-targeting, hepatitis B virus (HBV) and the numbers are increasing. On average, 10% of infected patients are unable to clear the virus and progress to a life-long chronic HBV infection. Children are at significant risk, as the progression to life-long chronic HBV infection is 90% for babies infected from mother-to-child.
There is no cure for chronic hepatitis B and up to 64 million patients will progress to severe liver-related diseases, resulting in close to 1 million annual deaths worldwide.